April Cuts Signal Earlier Price Erosion For Originator Drugs In Australia
This article was originally published in Scrip
Executive Summary
Originator pharmaceutical companies in Australia stand to take a hit on April 1 when the prices of 900 brand drugs reimbursed under the Pharmaceutical Benefits Scheme fall by 5% as a result of the first instalment of the new statutory price reduction (SPR), which affects medicines on the single-brand F1 formulary that have been listed on the PBS for at least five years.